Semaglutides
Common questions

Semaglutide FAQ: Straight Answers to the Most Common Questions

Semaglutide is a GLP-1 medication sold as Ozempic, Wegovy and Rybelsus, with trial weight loss around 14.9% at 68 weeks. This FAQ covers side effects, prices from $149 self-pay to a $675 list price in 2027, and safety questions including NAION and thyroid warnings.

Last checked ·39 sources cited·OzempicWegovy
Isometric clay scene of an injection pen surrounded by clay question marks and a stack of papers

Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.

Semaglutide is a prescription GLP-1 medication used for weight management, type 2 diabetes, and reducing the risk of chronic kidney disease and major cardiovascular events in certain patients with type 2 diabetes [1]. It is sold under the brand names Ozempic, Wegovy and Rybelsus, all made by Novo Nordisk, and was first approved by the FDA on December 5, 2017 under the Ozempic brand [1]. Injections are given once weekly and pills are taken once daily [1].

In the STEP 1 trial, adults without diabetes lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo [5]. Outside of trials, a real-world cohort that included people on semaglutide or tirzepatide lost an average of 8.7% in one year [23]. The most common side effects are gastrointestinal, and serious problems are uncommon but real, including a boxed warning about thyroid tumors seen in rodents [2][3][30].

What is semaglutide and how does it work?

Semaglutide is a GLP-1 receptor agonist, meaning it mimics the GLP-1 hormone that the gut naturally releases after eating [1]. It lowers appetite, delays gastric emptying, increases insulin release, and reduces the amount of glucagon released [1]. GLP-1 also acts in parts of the brain that control appetite and food intake [20].

Which semaglutide products are sold in the US, and what is each approved for?

Each brand is approved for specific conditions and patient groups [1].

Ozempic injection is approved to improve blood sugar control in adults with type 2 diabetes, to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of kidney function decline, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [3]. Ozempic tablets, in 1.5 mg, 4 mg and 9 mg strengths taken daily, are approved for blood sugar control in type 2 diabetes and for reducing major cardiovascular events in adults with type 2 diabetes at high risk [4].

Wegovy injection, in doses from 0.25 mg to 2.4 mg weekly, and Wegovy tablets, from 1.5 mg to 25 mg daily, are approved for weight reduction and for reducing major cardiovascular events in adults with established cardiovascular disease who have obesity or overweight [2]. The injection is also approved for weight management in patients with obesity aged 12 and older, and for noncirrhotic MASH (a form of fatty liver disease) in adults with moderate to advanced liver fibrosis [2]. A higher 7.2 mg weekly dose, called Wegovy HD, was approved for adults on March 19, 2026, just 54 days after filing [11].

What happened to Rybelsus?

An FDA approval letter signed January 30, 2026 changed the name of the Rybelsus formulation known as R2 to Ozempic tablets [13]. Rybelsus tablets come in 3 mg, 7 mg and 14 mg strengths, while Ozempic tablets come in 1.5 mg, 4 mg and 9 mg strengths [4]. The label states that Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis [4]. Both are taken once daily on an empty stomach in the morning with up to 4 ounces of water [4].

Is semaglutide the same as Mounjaro, Zepbound or Foundayo?

No. Mounjaro and Zepbound contain tirzepatide, a different drug that mimics two gut hormones, GIP and GLP-1 [14]. In a 72-week head-to-head trial of 751 adults with obesity but no type 2 diabetes, tirzepatide produced an average weight loss of 20.2% versus 13.7% for semaglutide [10].

Foundayo (orforglipron) is a once-daily GLP-1 pill for weight made by Eli Lilly that does not need to be taken on an empty stomach [35][12]. It is a different active ingredient from semaglutide.

How much weight do people lose on semaglutide in trials?

In STEP 1, 1,961 adults without diabetes took 2.4 mg weekly for 68 weeks. The semaglutide group lost an average of 14.9% of body weight, or 15.3 kg, versus 2.4% with placebo [5]. In the semaglutide group, 86.4% lost at least 5% of their body weight and 50.5% lost at least 15% [5].

Other trials found similar results. OASIS 4 tested a 25 mg daily pill in 307 adults with overweight or obesity and found a 13.6% average loss at week 64, versus 2.2% on placebo [9][12]. STEP UP T2D tested a 7.2 mg weekly dose in adults with obesity and type 2 diabetes and found a 13.2% loss over 72 weeks versus 3.9% on placebo — a result that applies only to that population, not to people without diabetes [8]. In STEP TEENS, adolescents aged 12 to 17 saw their BMI fall 16.1% over 68 weeks versus a 0.6% increase on placebo [27].

How much weight do people lose outside of trials?

A study of electronic health records from a health system in Ohio and Florida identified 7,881 adults with overweight or obesity, without type 2 diabetes, who started injectable semaglutide or tirzepatide between 2021 and 2023 [23]. Mean weight loss at one year was 8.7% [23].

Results tracked strongly with staying on the drug: people who stopped within 3 months lost 3.6%, those who stopped at 3 to 12 months lost 6.8%, and those who continued lost 11.9% [23]. A total of 80.8% were on low maintenance doses, and the authors pointed to discontinuation and lower doses as reasons real-world results fell short of phase 3 trials [23].

Does semaglutide cause muscle loss?

A DEXA substudy of STEP 1 followed 140 participants for 68 weeks [34]. Total fat mass fell 19.3% and visceral fat mass fell 27.4% [34]. Total lean mass also fell 9.7%, but because fat fell faster, lean mass as a share of total body mass rose by 3.0 percentage points [34].

What happens when you stop taking semaglutide?

In a one-year off-treatment extension of STEP 1, 327 participants were followed after stopping treatment [6]. They had lost an average of 17.3% of body weight by week 68, then regained 11.6 percentage points by week 120, leaving them a net 5.6% below their starting weight [6].

That means two-thirds of the prior weight loss was regained, and cardiometabolic improvements reverted toward baseline [6]. The authors concluded that obesity is chronic and ongoing treatment is required to maintain improvements in weight and health [6].

What are the most common side effects?

The most common adverse reactions are nausea, diarrhea, vomiting, constipation and abdominal pain [11][4]. In STEP 1, gastrointestinal events were typically transient and mild to moderate, and 4.5% of the semaglutide group stopped treatment because of them, versus 0.8% on placebo [5]. In OASIS 4, gastrointestinal events occurred in 74.0% of the oral semaglutide group versus 42.2% on placebo [9].

Some effects track with dose. In STEP UP T2D, dysesthesia (altered skin sensation) occurred in 18.9% of participants on 7.2 mg weekly versus 4.9% on 2.4 mg and none on placebo, while gastrointestinal events were similar between the two doses, 53.1% versus 51.5% [8]. The FDA has reported that altered skin sensation occurs more frequently at the higher Wegovy dosage and is conducting further investigations [11].

What serious risks are on the label?

Semaglutide products carry a boxed warning that the drug causes thyroid C-cell tumors in rodents at clinically relevant exposures, and that the human relevance has not been determined [2][3]. The drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [2][3].

The Wegovy label also lists warnings for acute pancreatitis, acute gallbladder disease, hypoglycemia when combined with insulin or insulin secretagogues, acute kidney injury from volume depletion, and severe gastrointestinal reactions [2]. Additional warnings cover anaphylaxis and angioedema, diabetic retinopathy complications, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation — patients are instructed to tell healthcare providers about planned surgeries or procedures [2].

A study by researchers from Harvard Medical School and the CDC estimated fewer than four emergency department visits per 1,000 patients taking semaglutide during 2022 and 2023. About 70% of those visits involved gastrointestinal problems, about 17% involved very low blood sugar, and about 6% involved allergic reactions [30].

Does semaglutide cause suicidal thoughts or vision loss?

On January 13, 2026, the FDA requested removal of the suicidal behavior and ideation warning from the labels of Saxenda, Wegovy and Zepbound, after a comprehensive review found no increased risk with GLP-1 receptor agonist medications [20]. The Wegovy label lists that warning as removed as of 02/2026 [2].

On vision: the European Medicines Agency’s safety committee concluded that NAION, an eye condition that may cause vision loss, is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people taking it, and that large studies in adults with type 2 diabetes suggest about a two-fold increase in risk [19]. Drugwatch reported in September 2026 that the FDA has yet to require a NAION warning on US semaglutide labels [26]. Drugwatch also reports that lawsuits over gastroparesis and vision loss have been grouped into two multidistrict litigations, totaling 4,022 lawsuits as of September 2026, with no global settlements announced [26].

Does semaglutide help the heart, kidneys or liver?

In the SELECT trial, 17,604 adults aged 45 or older with cardiovascular disease and a BMI of 27 or higher, but no diabetes, took 2.4 mg weekly. A primary cardiovascular event occurred in 6.5% of the semaglutide group versus 8.0% on placebo, a hazard ratio of 0.80, over a mean follow-up of 39.8 months [7].

In the FLOW trial, 3,533 adults with type 2 diabetes and chronic kidney disease took 1.0 mg weekly. The risk of major kidney disease events was 24% lower than placebo, and the trial was stopped early at a prespecified interim analysis [22].

For the liver, Wegovy received accelerated FDA approval on August 15, 2025 for noncirrhotic MASH with moderate to advanced fibrosis, making it the first GLP-1 approved for that condition [21]. In the ESSENCE trial at week 72, 63% achieved resolution of steatohepatitis versus 34% on placebo, and 37% achieved improvement in liver fibrosis versus 22% [21].

How much does semaglutide cost?

The Ozempic list price is $1,027.51 per pen or 30-tablet bottle, though most people do not pay list [14][15]. GoodRx puts the average retail price without insurance at about $1,200 per month — that is a retail figure, not a list price [15].

Price typeProductPrice
List priceOzempic pen or 30-tablet bottle$1,027.51 [14][15]
Average retail (GoodRx)Ozempic, no insuranceAbout $1,200/month [15]
Manufacturer self-payOzempic injection 0.25, 0.5 or 1 mg$349/month [14]
Manufacturer self-payOzempic injection 2 mg$499/month [14]
Manufacturer self-pay intro offerOzempic injection, new patients, first two months$199/month [14]
Manufacturer self-payOzempic pills 1.5 mg / 4 mg / 9 mg$149 / $199 / $299 per month [14]
Insured copayOzempic pills and injectionsAs low as $25 [14]
TrumpRx listingWegovy pill / Wegovy pen / Ozempic$149 / $199 / $199 per month [18]

Will the price go down, and does Medicare cover it?

On February 24, 2026, Novo Nordisk announced that effective January 1, 2027, the list price of Wegovy, Ozempic and Rybelsus will drop to $675 per month, cuts of roughly 50% for Wegovy and 35% for Ozempic [17]. The company stated the list price change does not affect direct-to-patient self-pay prices [17].

Medicare will run a short-term demonstration called the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027, giving eligible Part D enrollees access to certain GLP-1 drugs with a $50 copay. It operates outside the Part D benefit, so the deductible does not apply and there is no low-income subsidy [16].

US prices are high compared with other wealthy countries. Peterson-KFF found August 2023 list prices of $936 per month for Ozempic in the US versus $169 in Japan, and roughly ten times the prices in Sweden, the United Kingdom, Australia and France [29].

What about compounded or generic semaglutide?

Compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [25]. As of April 1, 2026, semaglutide does not appear on the FDA drug shortage list or the 503B bulks list [24]. FDA enforcement discretion for compounded semaglutide ended for 503A pharmacies after an April 24, 2025 court ruling, and for 503B outsourcing facilities as of May 22, 2025 [24]. The FDA has also issued warning letters to 30 telehealth companies over misleading compounded semaglutide claims [28].

On the generic front, Apotex, in partnership with Orbicular, received the first FDA tentative approval for a generic semaglutide injection on April 10, 2026; the product must wait for final approval eligibility before it can launch [28].

Sources

  1. Drugs.com. Semaglutide: Uses, Dosage, Side Effects, Brands. August 26, 2026.
  2. US Food and Drug Administration. WEGOVY (semaglutide) injection and tablets: prescribing information. 2026.
  3. National Library of Medicine DailyMed. OZEMPIC (semaglutide) injection, solution.
  4. US Food and Drug Administration. RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets: prescribing information. 2026.
  5. New England Journal of Medicine. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
  6. PubMed. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
  7. PubMed. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
  8. PubMed. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
  9. PubMed. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
  10. New England Journal of Medicine. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
  11. US Food and Drug Administration. FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide.
  12. AJMC. FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss. December 22, 2025.
  13. US Food and Drug Administration. Ozempic (semaglutide) tablets and Rybelsus (semaglutide) tablets: supplement approval letter. 2026.
  14. Drugs.com. How much does Ozempic cost with or without insurance? May 8, 2026.
  15. GoodRx. How Much Ozempic Costs Without Insurance — and 6 Ways to Save.
  16. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge.
  17. Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access.
  18. TrumpRx. TrumpRx: medication prices website.
  19. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy.
  20. US Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications.
  21. Novo Nordisk. Wegovy approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
  22. PubMed. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
  23. PubMed. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status.
  24. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
  25. US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
  26. Drugwatch. Ozempic Lawsuit: Blindness and Gastroparesis Claims. September 2026.
  27. PubMed. Once-Weekly Semaglutide in Adolescents with Obesity.
  28. Drug Topics. FDA Tentatively Approves Generic Version of Semaglutide. April 10, 2026.
  29. Peterson-KFF Health System Tracker. How do prices of drugs for weight loss in the U.S. compare to peer nations’ prices? August 17, 2023.
  30. Harvard Health. Harvard and CDC study: Serious side effects from semaglutide are uncommon.
  31. Mayo Clinic. Semaglutide (subcutaneous route) - Side effects & dosage.
  32. The Lancet. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
  33. PubMed Central. “Ozempic Face” in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.
  34. PubMed Central. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study.
  35. US Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program.

Frequently asked questions

Is Ozempic the same as Wegovy?

Both contain semaglutide and are made by Novo Nordisk, but they are approved for different uses. Ozempic is approved for type 2 diabetes, cardiovascular risk reduction, and kidney protection in adults with type 2 diabetes and chronic kidney disease. Wegovy is approved for weight reduction and cardiovascular risk reduction in adults with established cardiovascular disease.

Is there a semaglutide pill?

Yes. Ozempic tablets come in 1.5 mg, 4 mg and 9 mg strengths for type 2 diabetes, and Wegovy tablets come in 1.5 mg to 25 mg strengths for weight reduction. The pills are taken once daily on an empty stomach in the morning with up to 4 ounces of water. Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis.

Is there a generic semaglutide?

Not on the market yet. Apotex and Orbicular received the first FDA tentative approval for a generic semaglutide injection on April 10, 2026, but it must wait for final approval eligibility before launch. Compounded semaglutide is not FDA approved and is not reviewed for safety, effectiveness or quality.

Can teenagers take semaglutide?

Wegovy injection is FDA approved for weight management in patients with obesity aged 12 and older. In STEP TEENS, adolescents aged 12 to 17 saw their BMI fall 16.1% over 68 weeks on semaglutide versus a 0.6% increase on placebo.

Does semaglutide cause muscle loss?

Some lean mass is lost along with fat. In a 140-person STEP 1 substudy, total lean mass fell 9.7% over 68 weeks, but total fat mass fell 19.3% and visceral fat fell 27.4%, so lean mass as a share of total body mass actually rose by 3.0 percentage points.

Does semaglutide cause suicidal thoughts or vision loss?

On January 13, 2026, the FDA requested removal of the suicidal behavior and ideation warning from Saxenda, Wegovy and Zepbound labels after a review found no increased risk. On vision, the European Medicines Agency concluded NAION is a very rare side effect affecting up to 1 in 10,000 people taking semaglutide.

Is semaglutide stronger than tirzepatide?

In a 72-week head-to-head trial of 751 adults with obesity but no type 2 diabetes, tirzepatide produced an average weight loss of 20.2% versus 13.7% for semaglutide. Tirzepatide, sold as Mounjaro and Zepbound, mimics two gut hormones, GIP and GLP-1, while semaglutide mimics only GLP-1.

Will insurance cover semaglutide for weight loss?

It depends on the drug and the use. GoodRx notes that Ozempic is not approved for weight loss, so using it for that purpose is off-label and unlikely to be covered, while FDA-approved uses like type 2 diabetes are more often covered. Wegovy is approved for weight reduction. Eligible Medicare Part D enrollees can access certain GLP-1 drugs for a $50 copay through the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.